Stock listing

Dusseldorf:S49 Supernus Pharmaceuticals, Inc. Aktie

German listing (Dusseldorf) of Supernus Pharmaceuticals, Inc. · home listing NASDAQ:SUPN

Follow Supernus Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:SUPN

$39.84 USD +1.96 (+5.2%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SUPN

Since Jul 6, 2026 -15.7% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$37.77 – $40.43 USDOct 19, 2026
Volume
1.45M sharesOct 19, 2026
Market value
$2.32B USDAt the close on Oct 19, 2026 · price × 58.22M shares outstanding
Supernus Pharmaceuticals, Inc. logo
Ticker
Dusseldorf:S49
Asset type
Stock
Exchange
Dusseldorf
Currency
EUR

What changed lately

Calls

Upcoming

  • Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2026 Earnings Call

    Thu, Oct 29, 2026 · 4:30 PM ET

    Register

Replays

  • Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2026 Earnings Call

    Tue, Aug 04, 2026 · 4:30 PM ET

    Watch Transcript

  • Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2026 Earnings Call

    Tue, May 05, 2026 · 4:30 PM ET

    Watch Transcript

  • Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2025 Earnings Call

    Tue, Feb 24, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

Oct 19, 2026

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

Aug 31, 2026

Supernus Announces Second Quarter 2026 Financial Results

Aug 3, 2026

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Aug 3, 2026

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

Jul 22, 2026

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

Jul 14, 2026

Supernus Expands Partnership With MERGE as AI-Powered Agency of Record

Jun 17, 2026

Supernus Pharmaceuticals to Participate in June Investor Conferences

May 27, 2026

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

May 6, 2026

Supernus Announces First Quarter 2026 Financial Results

May 5, 2026

All Supernus Pharmaceuticals, Inc. news

Decks

Supernus Pharmaceuticals, Inc. on 6ix

News releases
19 in the last 12 months · 157 in all · newest Oct 19, 2026 · oldest 2019
Calls
24 calls with a replay · 24 with a transcript · latest Aug 4, 2026
Decks
16 decks · latest Aug 3, 2026

Where Supernus Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SUPN · Home listingNASDAQUnited StatesUSD
Lang & Schwarz:A1JX3ULang & SchwarzGermanyEUR
LS Exchange:A1JX3ULS ExchangeGermanyEUR
gettex:S49gettexGermanyEUR
BOATS:SUPNBOATSUnited StatesUSD
LSE:0LB2LSEUnited KingdomUSD
Frankfurt:S49FrankfurtGermanyEUR
BX Swiss:S49BX SwissSwitzerlandCHF
Dusseldorf:S49 · This pageDusseldorfGermanyEUR
Munich:S49MunichGermanyEUR
Stuttgart:S49StuttgartGermanyEUR
Tradegate:S49TradegateGermanyEUR

Log in to ask 6ix AI your own questions about Supernus Pharmaceuticals, Inc.